FENNEC PHARMACEUTICALS INC. Retained Earnings
FENNEC PHARMACEUTICALS INC. (FENC) had Retained Earnings of -$227.25 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$227.25M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$229.22M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$229.42M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$224.64M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$227.25M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$229.22M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | -$229.42M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$224.64M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$224.00M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$220.85M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$219.68M 10-K · filed 2026-03-27 | |
| 2024-09-30 | -$217.70M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | -$211.96M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$206.41M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | -$219.25M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $215.61M 10-K · filed 2024-03-29 | -$216.56M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$214.70M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | -$209.25M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | -$203.20M 10-K · filed 2024-03-29 | |
| 2022-09-30 | -$196.34M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$188.25M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | -$183.18M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$179.49M 10-K · filed 2023-03-29 | |
| 2021-09-30 | -$175.06M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | -$170.87M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | -$166.87M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$162.14M 10-K · filed 2022-02-28 | |
| 2020-09-30 | -$158.90M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | -$152.70M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | -$147.86M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | -$144.03M 10-K · filed 2021-03-30 | |
| 2019-09-30 | -$140.42M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | -$138.61M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | -$133.88M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | -$131.26M 10-K · filed 2020-02-14 | |
| 2018-09-30 | -$128.27M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | -$125.52M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | -$122.94M 10-Q · filed 2018-05-14 | |
| 2017-12-31 | -$121.37M 10-K · filed 2019-03-15 | |
| 2017-09-30 | -$119.08M 10-Q · filed 2017-11-13 | |
| 2017-06-30 | -$116.73M 10-Q · filed 2017-08-14 | |
| 2017-03-31 | -$115.13M 10-Q · filed 2017-05-12 | |
| 2016-12-31 | -$114.32M 10-K · filed 2018-03-28 | |
| 2016-09-30 | -$113.18M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $113.18M 10-Q · filed 2016-11-14 | -$112.68M 10-Q · filed 2016-08-12 |
| 2016-03-31 | -$111.95M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | -$111.53M 10-K · filed 2017-03-29 | |
| 2015-09-30 | -$110.99M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | -$110.87M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | -$110.70M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | -$110.87M 10-K · filed 2016-03-28 | |
| 2013-12-31 | -$108.70M 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |